About sixteen and a-half million Americans adults over the age of 20 years have coronary heart disease (Roger et al., 2010). every five minutes, 12 Americans will have some type of acute coronary event, nine of those will be myocardial infarctions, and five of those people will die (Roger et al., 2010). Myocardial infarction, or [...]
WEDNESDAY, Jan. 19 (HealthDay News) — Twenty percent of heart attack patients stand a good chance of suffering a second attack over the following three years, an event that is nearly as likely to be caused by a new blockage as by the original one, a new study suggests.
Bayer said Thursday that its Xarelto blood thinner, chemically known as rivaroxaban, helped patients who had experienced Acute Coronary Syndrome and will and the drug maker will file for market authorization by the end of the year.
Public release date: 11-Oct-2011 [ | E-mail | Share ] Contact: Anna-Sabine Ernstpresse@iqwig.de49-221-356-850Institute for Quality and Efficiency in Health Care
15:56, Tuesday 4 October 2011 (Adds details on drug, background)
Paris (ots/PRNewswire) – in new guidelines from the European Society of Cardiology (ESC), prasugrel – a once daily oral antiplatelet medicine – received a Class I recommendation for use in patients undergoing percutaneous coronary intervention (PCI) after experiencing a non-ST-segment elevation acute coronary syndrome (which comprises non-ST segment elevation myocardial infarction or NSTEMI – a [...]
Paris (ots/PRNewswire) – In new guidelines from the European Society of Cardiology (ESC), prasugrel – a once daily oral antiplatelet medicine – received a Class I recommendation for use in patients undergoing percutaneous coronary intervention (PCI) after experiencing a non-ST-segment elevation acute coronary syndrome (which comprises non-ST segment elevation myocardial infarction or NSTEMI – a [...]
Paris (ots/PRNewswire) – in new guidelines from the European Society of Cardiology (ESC), prasugrel – a once daily oral antiplatelet medicine – received a Class I recommendation for use in patients undergoing percutaneous coronary intervention (PCI) after experiencing a non-ST-segment elevation acute coronary syndrome (which comprises non-ST segment elevation myocardial infarction or NSTEMI – a [...]
Paris (ots/PRNewswire) – In new guidelines from the European Society of Cardiology (ESC), prasugrel – a once daily oral antiplatelet medicine – received a Class I recommendation for use in patients undergoing percutaneous coronary intervention (PCI) after experiencing a non-ST-segment elevation acute coronary syndrome (which comprises non-ST segment elevation myocardial infarction or NSTEMI – a [...]
Paris (ots/PRNewswire) – in new guidelines from the European Society of Cardiology (ESC), prasugrel – a once daily oral antiplatelet medicine – received a Class I recommendation for use in patients undergoing percutaneous coronary intervention (PCI) after experiencing a non-ST-segment elevation acute coronary syndrome (which comprises non-ST segment elevation myocardial infarction or NSTEMI – a [...]